The link between Parkinson's disease and breast and prostate cancers: A meta-analysis

References

• Doshay LJ. Problem situations in the treatment of paralysis agitans. J Am Med Assoc 1954;156:680–4.
   PubMed Web of Science ®Google Scholar
• Bajaj A, Driver JA, Schernhammer ES. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 2010;21:697–707.
   PubMed Web of Science ®Google Scholar
• Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011;76:2002–9.
   PubMed Web of Science ®Google Scholar
• Bourque M, Dluzen DE, Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 2009;30:142–57.
   PubMed Web of Science ®Google Scholar
• Key TJ. Hormones and cancer in humans. Mutat Res 1995;333:59–67.
   PubMed Web of Science ®Google Scholar
• Ko YJ, Balk SP. Targeting steroid hormone receptor pathways in the treatment of hormone dependent cancers. Curr Pharm Biotechnol 2004;5:459–70.
   PubMed Web of Science ®Google Scholar
• Giovannelli P, Di Donato M, Giraldi T, et al. Targeting rapid action of sex steroid receptors in breast and prostate cancers. Front Biosci 2011;16:2224–32.
   Web of Science ®Google Scholar
• Qiu L-X, Yuan H, Yu K-D, et al. Glutathione S-transferase M1 polymorphism and breast cancer susceptibility: a meta-analysis involving 46,281 subjects. Breast Cancer Res Treat 2010;121:703–8.
   PubMed Web of Science ®Google Scholar
• Cai Q, Wang Z, Zhang W, et al. Association between glutathione S-transferases M1 and T1 gene polymorphisms and prostate cancer risk: a systematic review and meta-analysis. Tumour Biol 2014;35:247–56.
   PubMed Web of Science ®Google Scholar
• Wang T, Wang B. Association between Glutathione S-transferase M1/Glutathione S-transferase T1 polymorphisms and Parkinson's disease: a meta-analysis. J Neurol Sci 2014;338:65–70.
   PubMed Web of Science ®Google Scholar
• Minami Y, Yamamoto R, Nishikouri M, et al. Mortality and cancer incidence in patients with Parkinson's disease. J Neurol 2000;247:429–34.
   PubMed Web of Science ®Google Scholar
• Olsen JH, Friis S, Frederiksen K, et al. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 2005;92:201–5.
   PubMed Web of Science ®Google Scholar
• Rugbjerg K, Friis S, Lassen CF, et al. Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease. Int J Cancer 2012;131:1904–11.
   PubMed Web of Science ®Google Scholar
• Kareus SA, Figueroa KP, Cannon-Albright LA, Pulst SM. Shared predispositions of parkinsonism and cancer: a population-based pedigree-linked study. Arch Neurol 2012;69:1572–7.
   PubMed Web of Science ®Google Scholar
• Elbaz A, Peterson BJ, Yang P, et al. Nonfatal cancer preceding Parkinson's disease: a case-control study. Epidemiology 2002;13:157–64.
   PubMed Web of Science ®Google Scholar
• Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology 2006;17:582–7.
   PubMed Web of Science ®Google Scholar
• Lo RY, Tanner CM, Van Den Eeden SK, et al. Comorbid cancer in Parkinson's disease. Mov Disord 2010;25:1809–17.
   PubMed Web of Science ®Google Scholar
• Becker C, Brobert GP, Johansson S, et al. Cancer risk in association with Parkinson disease: a population-based study. Parkinsonism Relat Disord 2010;16:186–90.
   PubMed Web of Science ®Google Scholar
• Fois AF, Wotton CJ, Yeates D, et al. Cancer in patients with motor neuron disease, multiple sclerosis and Parkinson's disease: record linkage studies. J Neurol Neurosurg Psychiatry 2010;81:215–21.
   PubMed Web of Science ®Google Scholar
• Mullen B, Muellerleile P, Bryant B. Cumulative meta-analysis: a consideration of indicators of sufficiency and stability. Pers Soc Psychol Bull 2001;27:1450–62.
   Web of Science ®Google Scholar
• D’Amelio M, Ragonese P, Morgante L, et al. Tumor diagnosis preceding Parkinson's disease: a case-control study. Mov Disord 2004;19:807–11.
   PubMed Web of Science ®Google Scholar
• Powers KM, Smith-Weller T, Franklin GM, et al Diabetes, smoking, and other medical conditions in relation to Parkinson's disease risk. Parkinsonism Relat Disord 2006;12:185–9.
   PubMed Web of Science ®Google Scholar
• Sun L-M, Liang J-A, Chang S-N, et al. Analysis of Parkinson's disease and subsequent cancer risk in Taiwan: a nationwide population-based cohort study. Neuroepidemiology 2011;37:114–9.
   PubMed Web of Science ®Google Scholar
• Alcalay RN, Clark LN, Marder KS, Bradley WEC. Lack of association between cancer history and PARKIN genotype: a family based study in PARKIN/Parkinson's families. Genes Chromosomes Cancer 2012;51:1109–13.
   PubMed Web of Science ®Google Scholar
• Wirdefeldt K, Weibull CE, Chen H, et al. Parkinson's disease and cancer: A register-based family study. Am J Epidemiol 2014;179:85–94.
   PubMed Web of Science ®Google Scholar
• Elbaz A, Peterson BJ, Bower JH, et al. Risk of cancer after the diagnosis of Parkinson's disease: a historical cohort study. Mov Disord 2005;20:719–25.
   PubMed Web of Science ®Google Scholar
• Driver JA, Logroscino G, Buring JE, et al. A prospective cohort study of cancer incidence following the diagnosis of Parkinson's disease. Cancer Epidemiol Biomarkers Prev 2007;16:1260–5.
   PubMed Web of Science ®Google Scholar
• Beyrouti MI, Beyrouti R, Beyrouti R, et al. Breast cancer in men. Presse Med. 2007;36:1919–24.
   PubMed Web of Science ®Google Scholar
• Andres SA, Smolenkova IA, Wittliff JL. Gender-associated expression of tumor markers and a small gene set in breast carcinoma. Breast 2014;23:226–33.
   PubMed Web of Science ®Google Scholar
• Wang T. Meta-analysis of PvuII, XbaI variants in ESR1 gene and the risk of Alzheimer's disease: The regional European difference. Neurosci Lett 2014;574C:41–6.
   Web of Science ®Google Scholar